Literature DB >> 6173738

Interferon-mediated depression of cytochrome P-450-dependent drug biotransformation.

G Singh, K W Renton.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6173738

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


× No keyword cloud information.
  8 in total

1.  A phase II study of ifosfamide and a2b-interferon in advanced non-small-cell lung cancer.

Authors:  M J Lind; S Gomm; A P Simmonds; L Ashcroft; A Kamthan; H Gurney; N Thatcher
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

Review 2.  Drug disposition in pathophysiological conditions.

Authors:  Adarsh Gandhi; Bhagavatula Moorthy; Romi Ghose
Journal:  Curr Drug Metab       Date:  2012-11       Impact factor: 3.731

Review 3.  Role of viral infections in the induction of adverse drug reactions.

Authors:  M Levy
Journal:  Drug Saf       Date:  1997-01       Impact factor: 5.228

Review 4.  Interferon-alpha in malignant and viral diseases. A review.

Authors:  R T Dorr
Journal:  Drugs       Date:  1993-02       Impact factor: 9.546

5.  Effects of acute febrile infectious diseases on the oral pharmacokinetics and effects of nitrendipine enantiomers and of bisoprolol.

Authors:  P A Soons; C Grib; D D Breimer; W Kirch
Journal:  Clin Pharmacokinet       Date:  1992-09       Impact factor: 6.447

6.  Influenza vaccination and theophylline pharmacokinetics in patients with chronic obstructive lung disease.

Authors:  B M Stults; P A Hashisaki
Journal:  West J Med       Date:  1983-11

Review 7.  Drug administration in chronic liver disease.

Authors:  J F Westphal; J M Brogard
Journal:  Drug Saf       Date:  1997-07       Impact factor: 5.228

8.  A randomized controlled trial to evaluate the role of interferon as initial and maintenance therapy in patients with follicular lymphoma.

Authors:  A Rohatiner; J Radford; D Deakin; H Earl; S B Love; O Price; A Wilson; T A Lister
Journal:  Br J Cancer       Date:  2001-07-06       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.